Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management
Open accessThe DOI matches its Crossref record; 129 of the 130 references it cites were found in a registry or an index; 84 of the 116 sources its claims cite were checked for support.
Abstract
The 'Body Mass Index' (BMI) is an anachronistic and outdated ratio that is used as an internationally accepted diagnostic criterion for obesity, and to prioritise, stratify, and outcome-assess its management options. On an individual level, the BMI has the potential to mislead, including inaccuracies in cardiovascular risk assessment. Furthermore, the BMI places excessive emphasis on a reduction in overall body weight (rather than optimised body composition) and contributes towards a misunderstanding of the quiddity of obesity and a dispassionate societal perspective and response to the global obesity problem. The overall objective of this review is to provide an overview of obesity that transitions away from the BMI and towards a novel vista: viewing obesity from the perspective of the skeletal muscle (SM). We resurrect the SM as a tissue hidden in plain sight and provide an overview of the key role that the SM plays in influencing metabolic health and efficiency. We discuss the complex interlinks between the SM and the adipose tissue (AT) through key myokines and adipokines, and argue that rather than two separate tissues, the SM and AT should be considered as a single entity: the 'Adipo-Muscle Axis'. We discuss the vicious circle of sarcopenic obesity, in which aging- and obesity-related decline in SM mass contributes to a worsened metabolic status and insulin resistance, which in turn further compounds SM mass and function. We provide an overview of the approaches that can mitigate against the decline in SM mass in the context of negative energy balance, including the optimisation of dietary protein intake and resistance physical exercises, and of novel molecules in development that target the SM, which will play an important role in the future management of obesity. Finally, we argue that the Adipo-Muscle Ratio (AMR) would provide a more clinically meaningful descriptor and definition of obesity than the BMI and would help to shift our focus regarding its effective management away from merely inducing weight loss and towards optimising the AMR with proper attention to the maintenance and augmentation of SM mass and function.
Overview
CoChat Summary
## TL;DR
This narrative review argues that skeletal muscle mass and function should be central to obesity management, not just body weight or BMI. The authors propose the Adipo–Muscle Ratio (AMR) as a more clinically meaningful obesity descriptor than BMI because it would capture both adipose tissue and skeletal muscle.
## Key findings
- Skeletal muscle is presented as a major determinant of metabolic health: it accounts for >80% of post-prandial glucose uptake and is described as the largest thermogenic organ and a key contributor to basal metabolic rate.
- Age-related decline in skeletal muscle mass was reported to start in the third decade and become noticeable beyond age 50; sarcopenic obesity is said to affect around 11% of older adults globally, with prevalence increasing beyond age 70.
- During sustained negative energy balance, the review states that ~25% of total body weight loss typically comes from fat-free mass, and in a review of GLP1-based therapies, fat-free mass loss was reported as 20–40% of total body weight loss, with most studies >25%.
- In a human randomized placebo-controlled trial of bimagrumab in adults with T2D and overweight/obesity over 48 weeks, the treatment group had 20.5% fat mass reduction, 3.6% lean mass increase, 9 cm waist circumference reduction, and 0.76% HbA1c reduction.
## Methods
- The paper is a narrative review of current literature, using PubMed.
- Search terms included “obesity,” “metabolism,” and “skeletal muscle”; the authors included peer-reviewed articles of many types, with no publication-date restrictions and English-language only.
- Study selection was based on the authors’ perceived clinical relevance, novelty, and relative size; the paper does not report a formal systematic search or meta-analysis.
## Limitations
- The paper states it is a narrative review, and it explicitly says the field is “vast and goes beyond the scope of this concise review.”
- The selection process was based on authors’ judgment rather than a predefined systematic or exhaustive protocol, which limits reproducibility and makes selection bias evident from the text.
- The paper is largely conceptual and argumentative; where it cites studies, it does not conduct a new empirical analysis, so many claims depend on previously published work rather than original data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
66 Valid · 2 Not valid · 16 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“There is a close physical proximity and interplay between the SM and AT regarding their anatomy and physiology, a scenario that is ripe for bidirectional paracrine effects.”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 1. Introduction The global prevalence of obesity now exceeds 890 million, with overweight affecting around 2.5 billion adults [1]. The World Health Organisation (WHO) classifies obesity as a non-infectious global pandemic [1]. This positioning of obesity as a worldwide public health problem promotes renewed and redoubled efforts to develop and implement effective preventive, diagnostic, and management strategies. Obesity confers a substantial burden upon humanity, with impairments in quality of life and wellbeing that stem from its association with wide-reaching negative sequelae including impairments in psychosocial functioning [2] and work productivity [3]. Furthermore, obesity contributes towards a major component of global healthcare expenditure [4], originating from both the direct costs of obesity management, and the indirect costs associated with >50 obesity-related co-morbidities. Indeed, many chronic diseases that manifest within the modern-day clinical arena stem directly from weight gain and obesity or are at least pathophysiologically vulnerable to the metabolic and/or physical ramifications of obesity. Within this context, Type 2 Diabetes Mellitus (T2D) is notable, including a plethora of other obesity-related metabolic dysfunctional conditions such as dyslipidaemia, dysglycaemia, hypertension, Obstructive Sleep Apnoea (OSA), Polycystic Ovary Syndrome (PCOS), and Metabolic-Associated Fatty Liver Disease (MAFLD) [5]. Furthermore, obesity is associated with multiple malignancies that in turn contribute towards premature mortality [6,7]. Insulin resistance (IR, often associated with oxidative stress and chronic inflammatory status) is a key mediator between obesity and its adverse metabolic sequelae, and develops in the context of excessive adiposity, particularly visceral adiposity and ectopic fat deposition (epicardial, hepatic, and intramyocellular lipid [IMCL]) [8]. Obesity is a heterogeneous clinical entity with distinct subtypes based on underlying genetic architecture and clinical phenotypic biomarkers that include measures of insulin sensitivity, glycaemia, physical fitness, body composition, and cardiovascular risk [9]. One key challenge for the field of obesity is the relative lack of refinement concerning its definition. This has compounded societal misunderstanding of obesity and perhaps has also contributed towards a widespread stigmatisation and dispassionate perspective of obesity [10]. Such lack of diagnostic refinement has also stymied the development and implementation of more effective and targeted management guidelines for obesity from esteemed societies and has resulted in an unfortunate over-emphasis on ‘percentage body weight loss’ as a key outcome variable for both the clinical management of obesity and the assessment of novel therapies for obesity. The concept of ‘body weight divided by height squared’ as an indicator of body size was originally proposed by Quetelet and was widely adopted as the ‘Body Mass Index’ in the 1980s [11,12]. Since then, our definition of obesity has rested firmly on the BMI. To account for differences in overall cardiovascular risk between ethnic-specific groups based on the BMI, NICE provide ethnic-specific cut-offs for the BMI to define obesity. However, population-based data from a cohort in England demonstrate marked ethnic-specific variance in the risk of developing T2D based on the BMI [13]. To validate and confirm these insights, there is a requirement for further similar population-based studies on cohorts from different geographical locations and with controls for potential confounders such as socio-economic groups. Most guidelines on obesity management from esteemed societies refer solely to the BMI [14]. There are various problems with the BMI as a key solitary definition of obesity (and by implication nutritional status), not the least of which being that the BMI fails as a meaningful clinical entity at extremes of body habitus (in which there is either excessive or severely diminished muscularity) [12]. Furthermore, the BMI provides no indication of overall adiposity or body fat distribution (including the amount of visceral or ectopic fat). At one extreme, there are people with excessive muscularity (such as body builders) with lean mass exceeding 70% in some cases, in whom the BMI is elevated accordingly. Such a clinical scenario creates potential for confusion and mismanagement based on the imaginatively impoverished and unidimensional, but internationally accepted, BMI criteria for defining obesity and stratifying and prioritising its management approach. Whilst some readers may think that using the example of a body builder is meaningless as the absence of excessive adiposity is obvious clinically, there are plenty of other examples that are relatively common within the clinical arena where accurate assessment of the musculature is challenging, in which cases the application of the BMI can genuinely create confusion and mismanagement. Furthermore, the example of body builders serves to illustrate the inadequacy of the BMI as a diagnostic and management-determining criterion for obesity: it is unfit for clinical usage in the 21st century. Most frustratingly, the BMI does not provide an accurate and reliable clinical indicator of cardiovascular risk, which would provide a more logical scaffold than the BMI on which to stratify obesity-focused management options. Although commonly used for individual patients, it is interesting to note that when the BMI was first conceived by Ancel Keys in the 1970s, it was proposed for use in population-wide epidemiological settings rather than as a diagnostic tool in individual patients [15], and as such the BMI is not even a component of some composite risk scores for the estimation of cardiovascular risk such as the Framingham score or PROCAM. A re-definition of obesity would require international consensus and demand focused attention on the quiddity of obesity. Whilst ‘excessive adiposity’ would generally be regarded as an essential criterion, there are many questions that relate to age- and sex-dependent normal ranges, inter- and intra-individual differences in adiposity, and the development and implementation of clinical tools (including non-invasive biomarkers) for the accurate and reliable measurement of adiposity, including its distribution and inflammatory status. The process of such a re-definition of obesity would also likely broaden our minds beyond the role of adiposity per se in both the development of obesity but also as a sole treatment target and clinical outcome measure. Indeed, to properly re-define obesity we would need to take a more holistic metabolic perspective of adiposity in its wider pathophysiological context and consider important roles of other tissues and processes. Within this wider context, the skeletal muscle (SM) looms as a cynosure, but it is eclipsed by its surrounding adiposity. Unfortunately, the role of the SM in the development and management of obesity has been neglected, partly because of an over-emphasis on the BMI, but also due to a greater focus on the adipose tissue (AT). Recently, however, the SM has received attention in relation to clinical data from Glucagon-like Peptide 1 (GLP1)-related pharmacotherapies for T2D and obesity. It is therefore both timely and topical to review this topic. There is a close physical proximity and interplay between the SM and AT regarding their anatomy and physiology, a scenario that is ripe for bidirectional paracrine effects. Changes within the AT influence the SM and vice versa. In this concise review, we provide an overview of the key physiological roles of the SM and discuss the multitudinous interactions between the SM and AT in the wider context of metabolic health. We discuss the association of obesity with sarcopenia (a form of SM atrophy), the metabolic sequelae of sarcopenia (including the key role of the SM in determining insulin sensitivity), and the inherent difficulties of clinical assessment of SM mass and functioning in the context of obesity. We discuss the mechanisms that contribute to the loss of SM mass during body weight loss (including in the context of pharmacotherapies for obesity) and strategies to preserve SM mass and functioning, including the recent development of pharmacotherapies that can preserve and maintain SM mass and thereby mitigate against the loss of SM mass during weight loss, and their likely positioning in future treatment algorithms for obesity. Finally, we outline a future scenario in which body composition (the ‘Adipo–Muscle Ratio [AMR]’) rather than the BMI assumes a central position as a re-defined diagnostic criterion for obesity, and in which key clinical outcome measures focus on changes in body composition (including the AMR) rather than the percentage of body weight loss per se.
What the sources say
- Partly supportedcites [36] An S.M. Cho S.H. Yoon J.C. Adipose Tissue and Metabolic Health Diabetes Metab. J. 2023 47 595 611 10.4093/dmj.2023.0011 37482656 PMC10555533 sourceExperimental — accuracy not yet measured
The Physiology sections describe adipose-derived factors with paracrine effects and report that adiponectin and BAT-derived myostatin act on skeletal muscle (pages unavailable in our copy). They do not establish close physical proximity between skeletal muscle and adipose tissue or bidirectional paracrine effects between them. (LLM, conf=0.85)
- Partly supportedcites [37] Rocha-Rodrigues S. Matos A. Afonso J. Mendes-Ferreira M. Abade E. Teixeira E. Silva B. Murawska-Cialowicz E. Oliveira M.J. Ribeiro R. Skeletal Muscle-Adipose Tissue-Tumor Axis: Molecular Mechanisms Linking Exercise Training in Prostate Cancer Int. J. Mol. Sci. 2021 22 4469 10.3390/ijms22094469 33922898 PMC8123194 sourceExperimental — accuracy not yet measured
The Introduction describes crosstalk between skeletal muscle and white adipose tissue, supporting the claim of physiological interplay. It describes myokines and adipokines as acting in an endocrine-dependent manner, however, and does not establish close physical proximity or bidirectional paracrine signaling between these two tissues. The “Bidirectional Paracrine Signaling” subsection instead concerns adipocytes and cancer cells; page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [38] Shen S. Liao Q. Zhang T. Pan R. Lin L. Myricanol modulates skeletal muscle-adipose tissue crosstalk to alleviate high-fat diet-induced obesity and insulin resistance Br. J. Pharmacol. 2019 176 3983 4001 10.1111/bph.14802 31339170 PMC6811775 sourceExperimental — accuracy not yet measured
Our copy supports the functional half of the claim: the Abstract and Introduction state that 'the crosstalk between adipose tissue and skeletal muscle is critical in maintaining insulin sensitivity and lipid homeostasis' and that 'Adipose and skeletal muscle secrete adipokines and myokines, respectively, to maintain metabolic homeostasis coordinately' (1. INTRODUCTION; Abstract), with the Discussion adding that irisin is 'not only a myokine but also an adipokine' (4. DISCUSSION). However, no passage in our copy addresses the anatomical element of the claim — there is no statement about close physical/anatomical proximity of SM and AT (searched: 'close physical proximity ... anatomy', 'bidirectional paracrine'). Moreover, the source hedges strict bidirectionality, noting 'it needs to be elucidated whether the adipose tissue secretes feedback signals to close the myocyte–adipocyte circle' (4. DISCUSSION), so presenting the arrangement as established bidirectional paracrine interplay runs ahead of the source. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Changes within the AT influence the SM and vice versa.”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 1. Introduction The global prevalence of obesity now exceeds 890 million, with overweight affecting around 2.5 billion adults [1]. The World Health Organisation (WHO) classifies obesity as a non-infectious global pandemic [1]. This positioning of obesity as a worldwide public health problem promotes renewed and redoubled efforts to develop and implement effective preventive, diagnostic, and management strategies. Obesity confers a substantial burden upon humanity, with impairments in quality of life and wellbeing that stem from its association with wide-reaching negative sequelae including impairments in psychosocial functioning [2] and work productivity [3]. Furthermore, obesity contributes towards a major component of global healthcare expenditure [4], originating from both the direct costs of obesity management, and the indirect costs associated with >50 obesity-related co-morbidities. Indeed, many chronic diseases that manifest within the modern-day clinical arena stem directly from weight gain and obesity or are at least pathophysiologically vulnerable to the metabolic and/or physical ramifications of obesity. Within this context, Type 2 Diabetes Mellitus (T2D) is notable, including a plethora of other obesity-related metabolic dysfunctional conditions such as dyslipidaemia, dysglycaemia, hypertension, Obstructive Sleep Apnoea (OSA), Polycystic Ovary Syndrome (PCOS), and Metabolic-Associated Fatty Liver Disease (MAFLD) [5]. Furthermore, obesity is associated with multiple malignancies that in turn contribute towards premature mortality [6,7]. Insulin resistance (IR, often associated with oxidative stress and chronic inflammatory status) is a key mediator between obesity and its adverse metabolic sequelae, and develops in the context of excessive adiposity, particularly visceral adiposity and ectopic fat deposition (epicardial, hepatic, and intramyocellular lipid [IMCL]) [8]. Obesity is a heterogeneous clinical entity with distinct subtypes based on underlying genetic architecture and clinical phenotypic biomarkers that include measures of insulin sensitivity, glycaemia, physical fitness, body composition, and cardiovascular risk [9]. One key challenge for the field of obesity is the relative lack of refinement concerning its definition. This has compounded societal misunderstanding of obesity and perhaps has also contributed towards a widespread stigmatisation and dispassionate perspective of obesity [10]. Such lack of diagnostic refinement has also stymied the development and implementation of more effective and targeted management guidelines for obesity from esteemed societies and has resulted in an unfortunate over-emphasis on ‘percentage body weight loss’ as a key outcome variable for both the clinical management of obesity and the assessment of novel therapies for obesity. The concept of ‘body weight divided by height squared’ as an indicator of body size was originally proposed by Quetelet and was widely adopted as the ‘Body Mass Index’ in the 1980s [11,12]. Since then, our definition of obesity has rested firmly on the BMI. To account for differences in overall cardiovascular risk between ethnic-specific groups based on the BMI, NICE provide ethnic-specific cut-offs for the BMI to define obesity. However, population-based data from a cohort in England demonstrate marked ethnic-specific variance in the risk of developing T2D based on the BMI [13]. To validate and confirm these insights, there is a requirement for further similar population-based studies on cohorts from different geographical locations and with controls for potential confounders such as socio-economic groups. Most guidelines on obesity management from esteemed societies refer solely to the BMI [14]. There are various problems with the BMI as a key solitary definition of obesity (and by implication nutritional status), not the least of which being that the BMI fails as a meaningful clinical entity at extremes of body habitus (in which there is either excessive or severely diminished muscularity) [12]. Furthermore, the BMI provides no indication of overall adiposity or body fat distribution (including the amount of visceral or ectopic fat). At one extreme, there are people with excessive muscularity (such as body builders) with lean mass exceeding 70% in some cases, in whom the BMI is elevated accordingly. Such a clinical scenario creates potential for confusion and mismanagement based on the imaginatively impoverished and unidimensional, but internationally accepted, BMI criteria for defining obesity and stratifying and prioritising its management approach. Whilst some readers may think that using the example of a body builder is meaningless as the absence of excessive adiposity is obvious clinically, there are plenty of other examples that are relatively common within the clinical arena where accurate assessment of the musculature is challenging, in which cases the application of the BMI can genuinely create confusion and mismanagement. Furthermore, the example of body builders serves to illustrate the inadequacy of the BMI as a diagnostic and management-determining criterion for obesity: it is unfit for clinical usage in the 21st century. Most frustratingly, the BMI does not provide an accurate and reliable clinical indicator of cardiovascular risk, which would provide a more logical scaffold than the BMI on which to stratify obesity-focused management options. Although commonly used for individual patients, it is interesting to note that when the BMI was first conceived by Ancel Keys in the 1970s, it was proposed for use in population-wide epidemiological settings rather than as a diagnostic tool in individual patients [15], and as such the BMI is not even a component of some composite risk scores for the estimation of cardiovascular risk such as the Framingham score or PROCAM. A re-definition of obesity would require international consensus and demand focused attention on the quiddity of obesity. Whilst ‘excessive adiposity’ would generally be regarded as an essential criterion, there are many questions that relate to age- and sex-dependent normal ranges, inter- and intra-individual differences in adiposity, and the development and implementation of clinical tools (including non-invasive biomarkers) for the accurate and reliable measurement of adiposity, including its distribution and inflammatory status. The process of such a re-definition of obesity would also likely broaden our minds beyond the role of adiposity per se in both the development of obesity but also as a sole treatment target and clinical outcome measure. Indeed, to properly re-define obesity we would need to take a more holistic metabolic perspective of adiposity in its wider pathophysiological context and consider important roles of other tissues and processes. Within this wider context, the skeletal muscle (SM) looms as a cynosure, but it is eclipsed by its surrounding adiposity. Unfortunately, the role of the SM in the development and management of obesity has been neglected, partly because of an over-emphasis on the BMI, but also due to a greater focus on the adipose tissue (AT). Recently, however, the SM has received attention in relation to clinical data from Glucagon-like Peptide 1 (GLP1)-related pharmacotherapies for T2D and obesity. It is therefore both timely and topical to review this topic. There is a close physical proximity and interplay between the SM and AT regarding their anatomy and physiology, a scenario that is ripe for bidirectional paracrine effects. Changes within the AT influence the SM and vice versa. In this concise review, we provide an overview of the key physiological roles of the SM and discuss the multitudinous interactions between the SM and AT in the wider context of metabolic health. We discuss the association of obesity with sarcopenia (a form of SM atrophy), the metabolic sequelae of sarcopenia (including the key role of the SM in determining insulin sensitivity), and the inherent difficulties of clinical assessment of SM mass and functioning in the context of obesity. We discuss the mechanisms that contribute to the loss of SM mass during body weight loss (including in the context of pharmacotherapies for obesity) and strategies to preserve SM mass and functioning, including the recent development of pharmacotherapies that can preserve and maintain SM mass and thereby mitigate against the loss of SM mass during weight loss, and their likely positioning in future treatment algorithms for obesity. Finally, we outline a future scenario in which body composition (the ‘Adipo–Muscle Ratio [AMR]’) rather than the BMI assumes a central position as a re-defined diagnostic criterion for obesity, and in which key clinical outcome measures focus on changes in body composition (including the AMR) rather than the percentage of body weight loss per se.
What the sources say
- Partly supportedcites [36] An S.M. Cho S.H. Yoon J.C. Adipose Tissue and Metabolic Health Diabetes Metab. J. 2023 47 595 611 10.4093/dmj.2023.0011 37482656 PMC10555533 sourceExperimental — accuracy not yet measured
The Physiology section (page unavailable) says adiponectin enhances muscle glucose uptake, and the thermogenic-adipose-tissue Physiology section says brown adipose tissue produces myostatin that acts on skeletal muscle. These support an adipose-tissue-to-skeletal-muscle effect, but the passages found do not establish the claimed reverse effect of skeletal muscle changes on adipose tissue. (LLM, conf=0.85)
- Supportedcites [37] Rocha-Rodrigues S. Matos A. Afonso J. Mendes-Ferreira M. Abade E. Teixeira E. Silva B. Murawska-Cialowicz E. Oliveira M.J. Ribeiro R. Skeletal Muscle-Adipose Tissue-Tumor Axis: Molecular Mechanisms Linking Exercise Training in Prostate Cancer Int. J. Mol. Sci. 2021 22 4469 10.3390/ijms22094469 33922898 PMC8123194 source
The Introduction describes communication between skeletal muscle and white adipose tissue through muscle-derived myokines and adipose-derived adipokines. Section 3.4 also describes effects in both directions: muscle-derived myokines can alter adipose tissue, while inflammatory adipokines and intramuscular adipose accumulation may affect skeletal-muscle insulin resistance. These passages support the broad claim of reciprocal influence. (LLM, conf=0.88)
- Supportedcites [38] Shen S. Liao Q. Zhang T. Pan R. Lin L. Myricanol modulates skeletal muscle-adipose tissue crosstalk to alleviate high-fat diet-induced obesity and insulin resistance Br. J. Pharmacol. 2019 176 3983 4001 10.1111/bph.14802 31339170 PMC6811775 source
The Abstract and Section 1 (INTRODUCTION) of our copy state that the crosstalk between adipose tissue and skeletal muscle is critical for insulin sensitivity and lipid/adiposity homeostasis, with the two tissues secreting adipokines and myokines 'to maintain metabolic homeostasis coordinately' — i.e. a bidirectional influence. Section 4 (DISCUSSION) reinforces both directions: skeletal-muscle irisin drives WAT browning while adipose tissue itself expresses Fndc5/secretes irisin and is a target of irisin ('not only a myokine but also an adipokine'), and dysregulated adipokines/myokines favour excess adiposity; the paper's own experimental design (Transwell co-culture of C2C12 myotubes with 3T3-L1 adipocytes, Section 2.4) is built on this reciprocal signalling. One mild caveat: the Discussion notes it 'needs to be elucidated whether the adipose tissue secretes feedback signals to close the myocyte–adipocyte circle,' but this does not contradict the general bidirectional-crosstalk statement the claim attributes. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As intimated earlier, there is a gradual reduction in SM mass with aging, which often becomes meaningful clinically from around the age of 50 years [17].”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 3. Results > 3.1. The Physiological Role of the SM and Its Decline with Aging
What the sources say
- Supportedcites [17] Merz K.E. Thurmond D.C. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake Compr. Physiol. 2020 10 785 809 10.1002/cphy.c190029 32940941 PMC8074531 source
The section “Links between aging and skeletal muscle insulin resistance” says that after ages 40–50, human skeletal muscle shows a gradual reduction in mass, accompanied by declining strength and function. This supports the claim’s approximate age and clinical significance, though the paper does not use the phrase “clinically meaningful.” (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Myokines (>600 peptides identified to date) influence the physiological function of the AT and other organs including bones and the brain [17].”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 3. Results > 3.2. The ‘Adipo–Muscle Axis’ and Relevance for Metabolic Health Having reviewed the essential role that the SM plays in the regulation of overall metabolic functioning and efficiency, and the progression of metabolic dysfunction with aging-associated diminishment of SM mass, in this section we consider the ‘Adipo–Muscle Axis’ (AMA): its physiological functioning and relevance for metabolic health (Figure 1). Although traditionally the physiological functioning and pathological potential of peripheral SM and AT have been considered as separate entities, the reality is that there is a close linkage between the SM and AT [36,37,38]. This close association manifests both anatomically, with the SM often surrounded and encased by the AT, and physiologically, through extensive crosstalk between the SM and AT that implicates bidirectional endocrine, autocrine, and paracrine effects. In this context, rather than taking the traditional perspective of considering each tissue type in isolation of the other, it is more meaningful to envision the SM and AT as a single functioning unit, at least from a metabolic perspective: an ‘AMA’. To understand the AMA better, it is useful to divide our discussion into molecules that originate from the SM (myokines) and from the AT (adipokines). This field is vast and goes beyond the scope of this concise review, and there are recent reviews that are more expansive [39]. Here, we simply provide a summary and discuss a few key myokines and adipokines to illustrate their roles in mediating crosstalk between the SM and AT.
What the sources say
- Supportedcites [17] Merz K.E. Thurmond D.C. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake Compr. Physiol. 2020 10 785 809 10.1002/cphy.c190029 32940941 PMC8074531 source
The “Mechanisms of myokine action” section says myokines mediate cross-talk with bone, brain, and adipose tissue, and that over 600 peptides produced and secreted by skeletal muscle have been identified. This supports the cited paraphrase. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Given its important role in glucose handling, the SM can be considered as a primary driver of whole-body IR [17].”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 3. Results > 3.1. The Physiological Role of the SM and Its Decline with Aging
What the sources say
- Supportedcites [17] Merz K.E. Thurmond D.C. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake Compr. Physiol. 2020 10 785 809 10.1002/cphy.c190029 32940941 PMC8074531 source
The section “Importance of skeletal muscle in insulin resistance” (page not available) explicitly calls skeletal muscle the primary driver of whole-body insulin resistance because it is the principal site of insulin-stimulated glucose uptake. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
53 more claims · 32 with their cited sources checked
Create a free account to see all 121 claims and to verify the 9 references still open.
- It may state two separate claims as one. 50
- Probably not a substantial claim. 26
Citations
Cites
A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810 · cited 1×
“The impact of spexin on IR in human SM is unknown.”
Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr
Janssen, I., Heymsfield, S. B., Wang, Z., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.1.81 · Cited by 3,087 · cited 3×
“Body height and weight accounted for around 50% of the variance in SM mass in both men and women, with linear and curvilinear relationships, respectively (the latter being due to the SM having less of a contribution towards weight gain with increasing body weight) [16].”
InfluentialLack of Exercise Is a Major Cause of Chronic Diseases
Booth, F. W., Roberts, C. K., & Laye, M. J. (2012) · Comprehensive Physiology · doi:10.1002/cphy.c110025 · Cited by 2,575 · cited 1×
“Unlike normal aging, the deleterious effects of secondary aging on the SM can be delayed through engagement in healthy lifestyle behaviours such as exercise and increased physical activity [17,35].”
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102 · cited 1×
“Furthermore, the SM accounts for >80% of glucose uptake in the post-prandial period following an oral glucose load, with linear increases in uptake over time [17,20].”
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“Indeed, with a weight loss of >10 Kg (and attendant loss of AT mass), there is recovery of β -cell function, and remission to a non-diabetic state in the context of T2D [22,23].”
Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479 · cited 1×
“Furthermore, obesity is associated with multiple malignancies that in turn contribute towards premature mortality [6,7].”
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007) · Diabetes · doi:10.2337/db06-1656 · Cited by 1,417 · cited 1×
“Although the mechanisms that control SM mass during NEB remain incompletely understood, AA tracer techniques have provided some useful insights [85].”
Morton, R. W., Murphy, K. T., McKellar, S. R., Schoenfeld, B. J., Henselmans, M., Helms, E., Aragon, A. A., Devries, M. C., Banfield, L., Krieger, J. W., et al. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2017-097608 · Cited by 1,269 · cited 1×
“Bimagrumab is a monoclonal antibody against ActRII, which could mitigate against the decline in SM mass in the context of GLP1-induced NEB.”
Holland, W. L., Brozinick, J. T., Wang, L.-P., Hawkins, E. D., Sargent, K. M., Liu, Y., Narra, K., Hoehn, K. L., Knotts, T. A., Siesky, A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.01.002 · Cited by 1,232 · cited 1×
“The inevitable loss of SM mass during NEB-induced body weight loss has important metabolic implications for dieting through the restriction of caloric intake.”
Muscle–Organ Crosstalk: The Emerging Roles of Myokines
Severinsen, M. C. K., & Pedersen, B. K. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa016 · Cited by 1,226 · cited 1×
“Although the majority of adipokines are implicated in promoting IR within the SM stemming from excessive AT mass, around half have also been demonstrated in vitro to have effects on myogenesis and/or SM hypertrophy [55].”
Goodpaster, B. H. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5755 · Cited by 1,194 · cited 1×
“Given the role for insulin in the regulation of caspase 3 activity through phosphatidylinositol-3 kinase (PI3K), this provides a mechanism whereby enhanced SM proteolysis occurs in response to hypoinsulinaemia (a physiological feature of NEB) [85,90].”
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164 · cited 2×
“In addition to the SM, there is also a strong interplay between the AT and IR [22].”
BMI-related errors in the measurement of obesity
Rothman, K. J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.87 · Cited by 1,139
Muscle strength and speed of movement in relation to age and muscle morphology
Larsson, L., Grimby, G., & Karlsson, J. (1979) · Journal of Applied Physiology · doi:10.1152/jappl.1979.46.3.451 · Cited by 1,135 · cited 1×
“Furthermore, there is also an aging-related decline in SM-mediated metabolic function that manifests with a diminishment of mitochondrial function and capacity for thermogenic energy expenditure [17,33].”
Leptin and Obesity: Role and clinical implication.
Obradovic, M., Sudar-Milovanovic, E., Soskic, S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T., & Isenovic, E. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.585887 · Cited by 1,121 · cited 1×
“This mechanism occurs through mitochondrial fission in response to an energy burden related to obesity and aging [43].”
Shafiee, G., Keshtkar, A., Soltani, A., Ahadi, Z., Larijani, B., & Heshmat, R. (2017) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-017-0302-x · Cited by 1,076 · cited 1×
“Indeed, following sustained periods of NEB, typically around 25% of total body weight loss stems from Fat-Free Mass (FFM), of which the SM forms a major component, with typically just 75% of body weight loss being from the AT [85,86].”
Pi-Sunyer, X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2074 · Cited by 1,025
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 1×
“Broadly, there are two strategies: (i) lifestyle and (ii) novel pharmacotherapies.”
Bolster, D. R., Crozier, S. J., Kimball, S. R., & Jefferson, L. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200171200 · Cited by 851 · cited 1×
“Broadly, there are two strategies: (i) lifestyle and (ii) novel pharmacotherapies.”
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813 · cited 1×
“Most guidelines on obesity management from esteemed societies refer solely to the BMI [14].”
Skov, A., Toubro, S., Rønn, B., Holm, L., & Astrup, A. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800867 · Cited by 743 · cited 1×
“…potential therapeutic means of maintaining SM mass in the context of NEB. Azelaprag as a novel Apelin receptor (APJ) agonist has recently undergone early phase human-based studies, with pre-clinical data suggesting favourable effects on body composition and optimised SM mass and quality [117,118].”
Obesity: Risk factors, complications, and strategies for sustainable long‐term weight management
Fruh, S. M. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12510 · Cited by 709 · cited 1×
“…with oxidative stress and chronic inflammatory status) is a key mediator between obesity and its adverse metabolic sequelae, and develops in the context of excessive adiposity, particularly visceral adiposity and ectopic fat deposition (epicardial, hepatic, and intramyocellular lipid [IMCL]) [8].”
Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease
Argilés, J. M., Campos, N., Lopez-Pedrosa, J. M., Rueda, R., & Rodriguez-Mañas, L. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.04.019 · Cited by 581
Maintenance of Skeletal Muscle Mitochondria in Health, Exercise, and Aging
Hood, D. A., Memme, J. M., Oliveira, A. N., & Triolo, M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114310 · Cited by 567 · cited 1×
“‘AMP-activated protein kinase’ (AMPK) also acts as a fuel sensor within the SM (with downstream inhibitory effects on mTORC1 activity [91]), and inhibits anabolic signalling pathways in response to limited energy availability and a reduction in cellular levels of ATP [85].”
Lowe, D. A., Wu, N., Rohdin-Bibby, L., Moore, A. H., Kelly, N., Liu, Y. E., Philip, E., Vittinghoff, E., Heymsfield, S. B., Olgin, J. E., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.4153 · Cited by 553 · cited 1×
“…emergence of GLP1-based therapies that enable a body weight loss of >20% has promoted a current unmet clinical need for novel pharmacotherapies that effectively preserve and augment SM mass and therefore mitigate against the decline in SM mass in the context of such GLP1-based therapy-induced NEB.”
Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later
Izquierdo, A. G., Crujeiras, A. B., Casanueva, F. F., & Carreira, M. C. (2019) · Nutrients · doi:10.3390/nu11112704 · Cited by 525 · cited 1×
“(In a rodent-based model of obesity, a reduction in IMCL content resulted in an improvement in insulin sensitivity within the SM [43,84].)”
Muscle, Bone, and Fat Crosstalk: The Biological Role of Myokines, Osteokines, and Adipokines
Kirk, B., Feehan, J., Lombardi, G., & Duque, G. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00599-y · Cited by 510 · cited 1×
“…to divide our discussion This field is vast and goes beyond the scope of this concise review, and there are recent reviews that are more expansive [39]. into molecules Here, we simply provide a summary and discuss a few key myokines and adipokines to illustrate their roles in mediating crosstalk…”
Nonlinear dynamics of multi-omics profiles during human aging
Shen, X., Wang, C., Zhou, X., Zhou, W., Hornburg, D., Wu, S., & Snyder, M. P. (2024) · Nature Aging · doi:10.1038/s43587-024-00692-2 · Cited by 500
Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake
Merz, K. E., & Thurmond, D. C. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190029 · Cited by 494
Farnsworth, E., Luscombe, N. D., Noakes, M., Wittert, G., Argyiou, E., & Clifton, P. M. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.1.31 · Cited by 438 · cited 1×
“…potential therapeutic means of maintaining SM mass in the context of NEB. Azelaprag as a novel Apelin receptor (APJ) agonist has recently undergone early phase human-based studies, with pre-clinical data suggesting favourable effects on body composition and optimised SM mass and quality [117,118].”
Role of Myokines in Regulating Skeletal Muscle Mass and Function
Lee, J. H., & Jun, H.-S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00042 · Cited by 432 · cited 1×
“%) within fast-twitch SM compared with wild-type littermates [55].”
Caleyachetty, R., Barber, T. M., Mohammed, N. I., Cappuccio, F. P., Hardy, R., Mathur, R., Banerjee, A., & Gill, P. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00088-7 · Cited by 429 · cited 1×
“However, population-based data from a cohort in England demonstrate marked ethnic-specific variance in the risk of developing T2D based on the BMI [13].”
Self-citationWard, L. C. (2019) · European Journal of Clinical Nutrition · doi:10.1038/s41430-018-0335-3 · Cited by 417 · cited 1×
“This sea change in our perspectives is long overdue, and would, in our view, improve the lives of people living with obesity, and also help to de-stigmatise obesity and its origins through improved public understanding, which in turn would help to facilitate a more compassionate societal approach.”
Weinheimer, E. M., Sands, L. P., & Campbell, W. W. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00298.x · Cited by 391
The Psychosocial Burden of Obesity
Sarwer, D. B., & Polonsky, H. M. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.04.016 · Cited by 391 · cited 1×
“Obesity confers a substantial burden upon humanity, with impairments in quality of life and wellbeing that stem from its association with wide-reaching negative sequelae including impairments in psychosocial functioning [2] and work productivity [3].”
Skeletal muscle design to meet functional demands
Lieber, R. L., & Ward, S. R. (2011) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2010.0316 · Cited by 377 · cited 3×
“The SM manifests as a wide variety of shapes and sizes for multiple tasks, with SM architecture and moment arms uniquely evolved for specific physical actions [18], under voluntary control by the somatic nervous system [17].”
Global prevalence of sarcopenic obesity in older adults: A systematic review and meta-analysis
Gao, Q., Mei, F., Shang, Y., Hu, K., Chen, F., Zhao, L., & Ma, B. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.06.009 · Cited by 376 · cited 1×
“This renewed interest in body composition stems from a new era in GLP1-based pharmacotherapies for obesity, in which a key benchmark of 20% total body weight loss has now been surpassed, for example, in response to the dual incretin (combined GLP1 and Glucose-dependent Insulinotropic Polypeptide…”
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338 · cited 2×
“Existing measures used in clinical practice provide insight into body composition, including, for example, the waist circumference and ‘Body–Adiposity Index’ (BAI: waist circumference/height), each of which provide a proxy measure of visceral fat content.”
Obesity Stigma: Causes, Consequences, and Potential Solutions
Westbury, S., Oyebode, O., van Rens, T., & Barber, T. M. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00495-3 · Cited by 317 · cited 1×
“This has compounded societal misunderstanding of obesity and perhaps has also contributed towards a widespread stigmatisation and dispassionate perspective of obesity [10].”
Self-citationAdipo-myokines: two sides of the same coin–mediators of inflammation and mediators of exercise
Raschke, S., & Eckel, J. (2013) · Mediators of Inflammation · doi:10.1155/2013/320724 · Cited by 296 · cited 1×
“In a rodent-based model, lipodystrophic ‘fat-free’ mice had a significantly reduced mass (15”
Markova, M., Pivovarova, O., Hornemann, S., Sucher, S., Frahnow, T., Wegner, K., Machann, J., Petzke, K. J., Hierholzer, J., Lichtinghagen, R., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.007 · Cited by 273 · cited 1×
“Therefore, there is a requirement for alternate strategies.”
Self-citationChanges of Adiponectin Oligomer Composition by Moderate Weight Reduction
Bobbert, T., Rochlitz, H., Wegewitz, U., Akpulat, S., Mai, K., Weickert, M. O., Möhlig, M., Pfeiffer, A. F. H., & Spranger, J. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2712 · Cited by 271 · cited 1×
“In addition to aging, other factors can contribute towards the development of sarcopenia even in the context of normal body weight, including, for example, neuroendocrine tumours and other forms of malignancies.”
Self-citationBody Mass Index, the Most Widely Used But Also Widely Criticized Index
Ortega, F. B., Sui, X., Lavie, C. J., & Blair, S. N. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.01.008 · Cited by 270
Oversecretion of interleukin-15 from skeletal muscle reduces adiposity
Quinn, L. S., Anderson, B. G., Strait-Bodey, L., Stroud, A. M., & Argilés, J. M. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90506.2008 · Cited by 267 · cited 1×
“Therefore, the normal development of SM mass and strength in rodents depends on leptin [55].”
Relation of muscle mass and fat mass to cardiovascular disease mortality
Srikanthan, P., Horwich, T. B., & Tseng, C. H. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.01.033 · Cited by 260 · cited 1×
“…with the AT) being a key component of obesity pathogenesis and development is under-appreciated, and this misconception places too much emphasis on body weight reduction as a treatment target, rather than the optimisation of body composition and specifically the maintenance of SM mass and function.”
White adipose tissue dysfunction in obesity and aging
Reyes-Farias, M., Fos-Domenech, J., Serra, D., Herrero, L., & Sánchez-Infantes, D. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114723 · Cited by 250
Progress and Challenges in the Biology of FNDC5 and Irisin
Maak, S., Norheim, F., Drevon, C. A., & Erickson, H. P. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab003 · Cited by 247 · cited 1×
“In summary, these animal models demonstrate metabolically beneficial effects of spexin on the SM to enhance the utilisation of glucose, thereby improving glucose homeostasis and insulin sensitivity [56].”
Rooks, D., Praestgaard, J., Hariry, S., Laurent, D., Petricoul, O., Perry, R. G., Lach‐Trifilieff, E., & Roubenoff, R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14927 · Cited by 244 · cited 2×
“Regarding the RBFC, there is controversy in the literature regarding its ability to predict the future risk of cardiovascular disease, with some negative studies [122–126], some positive studies [127,128], and some studies that are undecided regarding its clinical utility [129].”
Human skeletal muscle aging atlas
Kedlian, V. R., Wang, Y., Liu, T., Chen, X., Bolt, L., Tudor, C., Shen, Z., Fasouli, E. S., Prigmore, E., Kleshchevnikov, V., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00613-3 · Cited by 218 · cited 1×
“This gradual aging-related reduction in SM mass (trending towards a state of sarcopenia) contributes towards an overall decline in SM strength, function, and regenerative capacity, and is a key contributor to aging-related frailty with important implications for global health and economics [29–32].”
Hong, X., Isern, J., Campanario, S., Perdiguero, E., Ramírez-Pardo, I., Segalés, J., Hernansanz-Agustín, P., Curtabbi, A., Deryagin, O., Pollán, A., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.07.009 · Cited by 213 · cited 1×
“It is beyond the scope of this review to provide a detailed exposition of the intra-cellular regulation of the SM in response to NEB, which has been described eloquently elsewhere [85].”
The Effects of the Mediterranean Diet on Health and Gut Microbiota
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2023) · Nutrients · doi:10.3390/nu15092150 · Cited by 213 · cited 1×
“These therapeutic developments will have a broader clinical utility, including, for example, in the context of normal aging, obesity, and in concurrent chronic illness, all of which are associated with a diminution in SM mass.”
Self-citationLifetime sedentary living accelerates some aspects of secondary aging
Booth, F. W., Laye, M. J., & Roberts, M. D. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00420.2011 · Cited by 207 · cited 1×
“In addition to ‘normal aging’, enhanced metabolic dysfunction within the SM can also be influenced by T2D itself, other chronic diseases, and even a sedentary lifestyle, mediated through a process termed ‘secondary aging’ [17,34].”
Sarcopenic obesity: Emerging mechanisms and therapeutic potential
Axelrod, C. L., Dantas, W. S., & Kirwan, J. P. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155639 · Cited by 204 · cited 8×
“Indeed, following sustained periods of NEB, typically around 25% of total body weight loss stems from Fat-Free Mass (FFM), of which the SM forms a major component, with typically just 75% of body weight loss being from the AT [85,86].”
InfluentialIntramyocellular Lipid Content in Human Skeletal Muscle
Schrauwen‐Hinderling, V. B., Hesselink, M. K. C., Schrauwen, P., & Kooi, M. E. (2006) · Obesity · doi:10.1038/oby.2006.47 · Cited by 202 · cited 1×
“This forms the theme for the rest of this review.”
Raschke, S., Eckardt, K., Bjørklund Holven, K., Jensen, J., & Eckel, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062008 · Cited by 199 · cited 1×
“Although the majority of adipokines are implicated in promoting IR within the SM stemming from excessive AT mass, around half have also been demonstrated in vitro to have effects on myogenesis and/or SM hypertrophy [55].”
Weickert, M. O., Roden, M., Isken, F., Hoffmann, D., Nowotny, P., Osterhoff, M., Blaut, M., Alpert, C., Gögebakan, Ö., Bumke-Vogt, C., et al. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.004374 · Cited by 190 · cited 1×
“In the same model, whilst daily treatment with semaglutide induced a significant reduction in both lean and fat mass, combination therapy with semaglutide and bimagrumab resulted in a superior loss of fat mass with a simultaneous preservation of lean mass (despite a reduction in food intake) and an…”
Self-citationAdipose Tissue and Metabolic Health
An, S.-M., Cho, S.-H., & Yoon, J. C. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0011 · Cited by 184 · cited 2×
“…This close association manifests both anatomically, with the SM often surrounded and encased by the AT, and physiologically, through extensive crosstalk between the SM and AT that implicates bidirectional endocrine, autocrine, and paracrine effects. linkage between the SM and AT [36–38].”
Pasiakos, S. M., Vislocky, L. M., Carbone, J. W., Altieri, N., Konopelski, K., Freake, H. C., Anderson, J. M., Ferrando, A. A., Wolfe, R. R., & Rodriguez, N. R. (2010) · The Journal of Nutrition · doi:10.3945/jn.109.118372 · Cited by 176 · cited 1×
“Broadly, there are two strategies: (i) lifestyle and (ii) novel pharmacotherapies.”
Mascher, H., Tannerstedt, J., Brink-Elfegoun, T., Ekblom, B., Gustafsson, T., & Blomstrand, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00504.2007 · Cited by 163
Saboor Aftab, S. A., Kumar, S., & Barber, T. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12092 · Cited by 157 · cited 1×
“Interestingly, this proteolytic state in response to NEB becomes less pronounced and plateaus over an extended time period, presumably to enable the body to adapt and conserve protein and energy reserves [85,89].”
Self-citationMyint, P. K., Kwok, C. S., Luben, R. N., Wareham, N. J., & Khaw, K.-T. (2014) · Heart · doi:10.1136/heartjnl-2014-305816 · Cited by 151 · cited 1×
“…with the AT) being a key component of obesity pathogenesis and development is under-appreciated, and this misconception places too much emphasis on body weight reduction as a treatment target, rather than the optimisation of body composition and specifically the maintenance of SM mass and function.”
Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice
Li, X., Zhang, D., Vatner, D. F., Goedeke, L., Hirabara, S. M., Zhang, Y., Perry, R. J., & Shulman, G. I. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922169117 · Cited by 150 · cited 1×
“SO is a clinical condition defined by excessive adiposity and a low SM mass and/or function [73] and affects around 11% of older adults globally, with a significant increase in prevalence beyond the age of 70 years [43,74].”
Skeletal muscle responses to negative energy balance: Effects of dietary protein
Carbone, J. W., McClung, J. P., & Pasiakos, S. M. (2012) · Advances in Nutrition · doi:10.3945/an.111.001792 · Cited by 138 · cited 1×
“Broadly, there are two strategies: (i) lifestyle and (ii) novel pharmacotherapies.”
Taylor, A. H., Doust, J., & Webborn, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.9.595 · Cited by 130 · cited 1×
“Indeed, IR within the SM can develop independently of and decades prior to the onset of β -cell failure and the onset of T2D in those at high metabolic risk [17,21].”
Signalling mechanisms linking hepatic glucose and lipid metabolism
Weickert, M. O., & Pfeiffer, A. F. H. (2006) · Diabetologia · doi:10.1007/s00125-006-0295-3 · Cited by 127 · cited 1×
“In the same model, whilst daily treatment with semaglutide induced a significant reduction in both lean and fat mass, combination therapy with semaglutide and bimagrumab resulted in a superior loss of fat mass with a simultaneous preservation of lean mass (despite a reduction in food intake) and an…”
Self-citationBeavers, K. M., Lyles, M. F., Davis, C. C., Wang, X., Beavers, D. P., & Nicklas, B. J. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.004895 · Cited by 126 · cited 1×
“Broadly, there are two strategies: (i) lifestyle and (ii) novel pharmacotherapies.”
Nunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., Calhoun, R., Lee, M., Holman, C. D., Baur, J. A., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101880 · Cited by 126 · cited 3×
“In this review, we have argued for the SM as a key determinant of overall metabolic functioning and efficiency, including the handling of macronutrients, IR, and BMR.”
InfluentialLiu, J., Yang, X., Yu, S., & Zheng, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1286-1_8 · Cited by 125 · cited 1×
“Mitochondrial fitness or dysfunction underlies SM function, and it is notable that even without physical activity weight loss results in extensive changes in mitochondrial function that mediate improved metabolic efficiency of the SM [79,80].”
Verreijen, A. M., Engberink, M. F., Memelink, R. G., van der Plas, S. E., Visser, M., & Weijs, P. J. M. (2017) · Nutrition Journal · doi:10.1186/s12937-017-0229-6 · Cited by 121 · cited 1×
“Bimagrumab was studied in a further human-based randomised placebo-controlled study in community-dwelling older adults with sarcopenia and mobility limitations [116].”
Pasiakos, S. M., McClung, H. L., McClung, J. P., Margolis, L. M., Andersen, N. E., Cloutier, G. J., Pikosky, M. A., Rood, J. C., Fielding, R. A., & Young, A. J. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.017061 · Cited by 118 · cited 1×
“In a recently reported rodent-based model, rimonabant—an older centrally acting CB1R inverse agonist—partially restored SM function and induced favourable metabolic changes in the AT and liver [121].”
Protein Quantity and Quality at Levels above the RDA Improves Adult Weight Loss
Layman, D. K. (2004) · Journal of the American College of Nutrition · doi:10.1080/07315724.2004.10719435 · Cited by 114 · cited 1×
“In a recently reported rodent-based model, rimonabant—an older centrally acting CB1R inverse agonist—partially restored SM function and induced favourable metabolic changes in the AT and liver [121].”
Templeman, I., Smith, H. A., Chowdhury, E., Chen, Y.-C., Carroll, H., Johnson-Bonson, D., Hengist, A., Smith, R., Creighton, J., Clayton, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd8034 · Cited by 113 · cited 1×
“…emergence of GLP1-based therapies that enable a body weight loss of >20% has promoted a current unmet clinical need for novel pharmacotherapies that effectively preserve and augment SM mass and therefore mitigate against the decline in SM mass in the context of such GLP1-based therapy-induced NEB.”
Gortan Cappellari, G., Guillet, C., Poggiogalle, E., Ballesteros Pomar, M. D., Batsis, J. A., Boirie, Y., Breton, I., Frara, S., Genton, L., Gepner, Y., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.02.018 · Cited by 113 · cited 1×
“This renewed interest in body composition stems from a new era in GLP1-based pharmacotherapies for obesity, in which a key benchmark of 20% total body weight loss has now been surpassed, for example, in response to the dual incretin (combined GLP1 and Glucose-dependent Insulinotropic Polypeptide…”
Targeting the apelin system for the treatment of cardiovascular diseases
Chapman, F. A., Maguire, J. J., Newby, D. E., Davenport, A. P., & Dhaun, N. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad171 · Cited by 104 · cited 1×
“Such a scenario should prompt a redoubling of management strategies to reduce the AMR, thereby improving cardiometabolic risk, and these types of cases should be prioritised.”
Important Trends in UCP3 Investigation
Pohl, E. E., Rupprecht, A., Macher, G., & Hilse, K. E. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00470 · Cited by 102 · cited 1×
“Uncoupling of oxidative phosphorylation within the SM via the SERCA pump can also occur through the action of uncoupling protein 3 (UCP3) [24,27].”
Weight Loss in Type 2 Diabetic Patients
Pi-Sunyer, F. X. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1526 · Cited by 100 · cited 1×
“Broadly, there are two strategies: (i) lifestyle and (ii) novel pharmacotherapies.”
Late‐onset hypogonadism: metabolic impact
Grossmann, M., Ng Tang Fui, M., & Cheung, A. S. (2020) · Andrology · doi:10.1111/andr.12705 · Cited by 95 · cited 1×
“(Other studies have shown discordant SM protein turnover data in response to NEB that may have resulted from differences in study design, populations, or dietary interventions [85].)”
Shen, S., Liao, Q., Zhang, T., Pan, R., & Lin, L. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14802 · Cited by 86 · cited 2×
“…This close association manifests both anatomically, with the SM often surrounded and encased by the AT, and physiologically, through extensive crosstalk between the SM and AT that implicates bidirectional endocrine, autocrine, and paracrine effects. linkage between the SM and AT [36–38].”
Role of SERCA Pump in Muscle Thermogenesis and Metabolism
Periasamy, M., Maurya, S. K., Sahoo, S. K., Singh, S., Reis, F. C. G., & Bal, N. C. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c160030 · Cited by 85
Albrecht, E., Schering, L., Buck, F., Vlach, K., Schober, H.-C., Drevon, C. A., & Maak, S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.016 · Cited by 85 · cited 1×
“In summary, these animal models demonstrate metabolically beneficial effects of spexin on the SM to enhance the utilisation of glucose, thereby improving glucose homeostasis and insulin sensitivity [56].”
Adipose and skeletal muscle thermogenesis: studies from large animals
Fuller-Jackson, J.-P., & Henry, B. A. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0090 · Cited by 84
Konieczna, J., Ruiz-Canela, M., Galmes-Panades, A. M., Abete, I., Babio, N., Fiol, M., Martín-Sánchez, V., Estruch, R., Vidal, J., Buil-Cosiales, P., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.37994 · Cited by 78 · cited 1×
“In recent years, there has been a lot of interest in the therapeutic potential of myostatin inhibition to combat muscle atrophy [17].”
Madiraju, A. K., Alves, T. C., Zhao, X., Cline, G. W., Zhang, D., Bhanot, S., Samuel, V. T., Kibbey, R. G., & Shulman, G. I. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606022113 · Cited by 71 · cited 1×
“In the bimagrumab group, there was a statistically significant increase in thigh muscle volume (7.72% increase at 16 weeks), and clinically meaningful improvements in gait speed for those participants with a slower walking speed at baseline [116].”
InfluentialEffect of reduced dietary intake on energy expenditure, protein turnover, and glucose cycling in man
Stein, T. P., Rumpler, W. V., Leskiw, M. J., Schluter, M. D., Staples, R., & Bodwell, C. E. (1991) · Metabolism · doi:10.1016/0026-0495(91)90228-o · Cited by 67 · cited 1×
“Broadly, there are two strategies: (i) lifestyle and (ii) novel pharmacotherapies.”
Cecchini, M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0206703 · Cited by 66 · cited 1×
“Furthermore, obesity contributes towards a major component of global healthcare expenditure [4], originating from both the direct costs of obesity management, and the indirect costs associated with >50 obesity-related co-morbidities.”
Adipose–Muscle Crosstalk in Age-Related Metabolic Disorders: The Emerging Roles of Adipo-Myokines
Fang, P., She, Y., Yu, M., Min, W., Shang, W., & Zhang, Z. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101829 · Cited by 62 · cited 9×
“In addition to the aging-related decline in SM mass and function, there are other obesity-related factors that can diminish SM mass through the effects of adipokines and cytokines outlined in the last section.”
InfluentialFndc5 loss‐of‐function attenuates exercise‐induced browning of white adipose tissue in mice
Xiong, Y., Wu, Z., Zhang, B., Wang, C., Mao, F., Liu, X., Hu, K., Sun, X., Jin, W., & Kuang, S. (2019) · The FASEB Journal · doi:10.1096/fj.201801754rr · Cited by 61 · cited 1×
“In humans, weight loss is associated with an improved metabolic efficiency within the SM, including a decrease in the ratio of glycolytic to oxidative activity [65].”
Bohn, B., Müller, M. J., Ŝimić-Schleicher, G., Kieß, W., Siegfried, W., Oelert, M., Tuschy, S., Berghem, S., & Holl, R. W. (2015) · Obesity Facts · doi:10.1159/000381227 · Cited by 58
Effects of weight loss and leptin on skeletal muscle in human subjects
Baldwin, K. M., Joanisse, D. R., Haddad, F., Goldsmith, R. L., Gallagher, D., Pavlovich, K. H., Shamoon, E. L., Leibel, R. L., & Rosenbaum, M. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00397.2011 · Cited by 58
Leptin mediates the regulation of muscle mass and strength by adipose tissue
Collins, K. H., Gui, C., Ely, E. V., Lenz, K. L., Harris, C. A., Guilak, F., & Meyer, G. A. (2022) · The Journal of Physiology · doi:10.1113/jp283034 · Cited by 54 · cited 4×
“As alluded to earlier, the development of sarcopenia has serious negative consequences for metabolic health and efficiency [43].”
InfluentialNutritional Modulation of Insulin Resistance
Weickert, M. O. (2012) · Scientifica · doi:10.6064/2012/424780 · Cited by 53 · cited 1×
“Broadly, there are two strategies: (i) lifestyle and (ii) novel pharmacotherapies.”
Self-citationIncreased Protein Maintains Nitrogen Balance during Exercise-Induced Energy Deficit
PIKOSKY, M. A., SMITH, T. J., GREDIAGIN, A., CASTANEDA-SCEPPA, C., BYERLEY, L., GLICKMAN, E. L., & YOUNG, A. J. (2008) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31815f6643 · Cited by 52 · cited 1×
“In addition to improved body composition, INV-202 may also have anti-fibrotic effects that are desirable for optimised kidney and liver functions in obesity and T2D [120].”
Effects of dietary protein on the composition of weight loss in post-menopaus al women
Gordons, M. M., Bopp, M. J., Easter, L., Miller, G. D., Lyles, M. F., Houston, D. K., Nicklas, B. J., & Kritchevsky, S. B. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02983202 · Cited by 50 · cited 2×
“Beyond the myostatin and Activin A pathway, the bioactive peptide Apelin (produced and secreted by the AT) provides an alternate potential therapeutic means of maintaining SM mass in the context of NEB. Azelaprag as a novel Apelin receptor (APJ) agonist has recently undergone early phase…”
Pruszyńska‐Oszmałek, E., Sassek, M., Szczepankiewicz, D., Nowak, K. W., & Kolodziejski, P. A. (2020) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2020.113615 · Cited by 48 · cited 1×
“In addition to the aging-related decline in SM mass and function, there are other obesity-related factors that can diminish SM mass through the effects of adipokines and cytokines outlined in the last section.”
Di Rosa, C., Lattanzi, G., Spiezia, C., Imperia, E., Piccirilli, S., Beato, I., Gaspa, G., Micheli, V., De Joannon, F., Vallecorsa, N., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192013040 · Cited by 47 · cited 1×
“In recent years, there has been a lot of interest in the therapeutic potential of myostatin inhibition to combat muscle atrophy [17].”
Dubin, R. L., Heymsfield, S. B., Ravussin, E., & Greenway, F. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15913 · Cited by 47 · cited 1×
“Broadly, there are two strategies: (i) lifestyle and (ii) novel pharmacotherapies.”
Overweight, obesity and work functioning: The role of working-time arrangements
Nigatu, Y. T., van de Ven, H. A., van der Klink, J. J. L., Brouwer, S., Reijneveld, S. A., & Bültmann, U. (2015) · Applied Ergonomics · doi:10.1016/j.apergo.2015.07.016 · Cited by 45
Identifying obesity subtypes: A review of studies utilising clinical biomarkers and genetic data
Abraham, A., & Yaghootkar, H. (2023) · Diabetic Medicine · doi:10.1111/dme.15226 · Cited by 43 · cited 1×
“Obesity is a heterogeneous clinical entity with distinct subtypes based on underlying genetic architecture and clinical phenotypic biomarkers that include measures of insulin sensitivity, glycaemia, physical fitness, body composition, and cardiovascular risk [9].”
Si, S., Tewara, M. A., Ji, X., Wang, Y., Liu, Y., Dai, X., Wang, Z., & Xue, F. (2020) · Cancer Medicine · doi:10.1002/cam4.3076 · Cited by 42 · cited 1×
“…with the AT) being a key component of obesity pathogenesis and development is under-appreciated, and this misconception places too much emphasis on body weight reduction as a treatment target, rather than the optimisation of body composition and specifically the maintenance of SM mass and function.”
Pervin, S., Reddy, S. T., & Singh, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.653179 · Cited by 42 · cited 1×
“In a further rodent-based model of IR, it was shown that spexin treatment resulted in an upregulation in the expression of genes implicated in the metabolism of glucose and lipids, including GLUT4 and PGC1 α , thereby increasing insulin sensitivity within the SM [56,61].”
Spexin ameliorates skeletal muscle insulin resistance through activation of GAL2 receptor
Yu, M., Wang, M., Han, S., Han, L., Kan, Y., Zhao, J., Yu, X., Yan, J., Yu, J. Z., Zhang, Z., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174731 · Cited by 42 · cited 1×
“Excessive adiposity can be associated with an inflammatory response within the AT, including the release of certain pro-inflammatory cytokines like IL-6 and TNF-α , which in turn can adversely affect the SM directly and be associated with a diminished SM mass and strength [43,75].”
Crater, G. D., Lalonde, K., Ravenelle, F., Harvey, M., & Després, J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15353 · Cited by 41
Skeletal muscle non-shivering thermogenesis as an attractive strategy to combat obesity
Li, H., Wang, C., Li, L., & Li, L. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119024 · Cited by 38 · cited 9×
“Through uncoupling ATP generation, intracellular energy is released as heat [24,25].”
InfluentialHattersley, J. G., Pfeiffer, A. F. H., Roden, M., Petzke, K.-J., Hoffmann, D., Rudovich, N. N., Randeva, H. S., Vatish, M., Osterhoff, M., Goegebakan, Ö., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2302 · Cited by 37 · cited 1×
“In a recently reported rodent-based model, rimonabant—an older centrally acting CB1R inverse agonist—partially restored SM function and induced favourable metabolic changes in the AT and liver [121].”
Self-citationCastro‐Sepúlveda, M., Fernández‐Verdejo, R., Zbinden‐Foncea, H., & Rieusset, J. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155578 · Cited by 37 · cited 1×
“‘AMP-activated protein kinase’ (AMPK) also acts as a fuel sensor within the SM (with downstream inhibitory effects on mTORC1 activity [91]), and inhibits anabolic signalling pathways in response to limited energy availability and a reduction in cellular levels of ATP [85].”
Tomiya, S., Tamura, Y., Kouzaki, K., Kotani, T., Wakabayashi, Y., Noda, M., & Nakazato, K. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00118.2019 · Cited by 35 · cited 1×
“The activity of SLN is influenced by exercise, endoplasmic reticulum (ER) stress, muscle atrophy, and the actions of various hormones that include thyroid hormones and glucocorticoids [24,26].”
Shen, W., Cai, L., Wang, B., Wang, Y., Wang, N., & Lu, Y. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s423272 · Cited by 34 · cited 1×
“…with the AT) being a key component of obesity pathogenesis and development is under-appreciated, and this misconception places too much emphasis on body weight reduction as a treatment target, rather than the optimisation of body composition and specifically the maintenance of SM mass and function.”
Zhang, L., Li, G., She, Y., & Zhang, Z. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00207 · Cited by 33 · cited 1×
“In turn, MOSH can worsen body composition, with further diminishment of SM mass, quality, and function through impaired muscle protein synthesis and myogenic differentiation, and stimulation of adipogenesis [43,77].”
Corrigendum to: “Muscle-Organ Crosstalk: The Emerging Roles of Myokines”
(2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa024 · Cited by 30 · cited 1×
“Although the majority of adipokines are implicated in promoting IR within the SM stemming from excessive AT mass, around half have also been demonstrated in vitro to have effects on myogenesis and/or SM hypertrophy [55].”
Body composition measures and cardiovascular risk in high-risk ethnic groups
Diemer, F. S., Brewster, L. M., Haan, Y. C., Oehlers, G. P., van Montfrans, G. A., & van Venrooij, L. M. W. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.11.012 · Cited by 29
Rasmussen, N. (2019) · Journal of the History of the Behavioral Sciences · doi:10.1002/jhbs.21991 · Cited by 28
Weight loss increases skeletal muscle mitochondrial energy efficiency in obese mice
Ferrara, P. J., Lang, M. J., Johnson, J. M., Watanabe, S., McLaughlin, K. L., Alan Maschek, J., Verkerke, A. R. P., Siripoksup, P., Chaix, A., Cox, J. E., et al. (2023) · Life Metabolism · doi:10.1093/lifemeta/load014 · Cited by 26
Emerging central and peripheral actions of spexin in feeding behavior, leptin resistance and obesity
Yu, M., Ju, M., Fang, P., & Zhang, Z. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115121 · Cited by 24 · cited 1×
“In addition to the aging-related decline in SM mass and function, there are other obesity-related factors that can diminish SM mass through the effects of adipokines and cytokines outlined in the last section.”
Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2023) · Metabolites · doi:10.3390/metabo13060757 · Cited by 24 · cited 1×
“…Type 2 Diabetes Mellitus (T2D) is notable, including a plethora of other obesity-related metabolic dysfunctional conditions such as dyslipidaemia, dysglycaemia, hypertension, Obstructive Sleep Apnoea (OSA), Polycystic Ovary Syndrome (PCOS), and Metabolic-Associated Fatty Liver Disease (MAFLD) [5].”
Self-citationCerebral Benefits Induced by Electrical Muscle Stimulation: Evidence from a Human and Rat Study
Chaney, R., Leger, C., Wirtz, J., Fontanier, E., Méloux, A., Quirié, A., Martin, A., Prigent‐Tessier, A., & Garnier, P. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031883 · Cited by 20 · cited 1×
“These data promote the exploration of spexin as a possible future therapeutic target for IR or even as a biomarker for metabolic dysfunction [56].”
Jacquot, L., Pointeau, O., Roger-Villeboeuf, C., Passilly‐Degrace, P., Belkaid, R., Regazzoni, I., Leemput, J., Buch, C., Demizieux, L., Vergès, B. L., et al. (2023) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1138416 · Cited by 18 · cited 1×
“As outlined, future treatment algorithms will include novel pharmacotherapies that target both the SM and AT, thereby directly improving the AMR.”
Rocha-Rodrigues, S., Matos, A., Afonso, J., Mendes-Ferreira, M., Abade, E., Teixeira, E., Silva, B., Murawska-Ciałowicz, E., Oliveira, M. J., & Ribeiro, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094469 · Cited by 17
Clement, D. S. V. M., van Leerdam, M. E., Tesselaar, M. E. T., Cananea, E., Martin, W., Weickert, M. O., Sarker, D., Ramage, J. K., & Srirajaskanthan, R. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13376 · Cited by 17 · cited 1×
“The issue of loss of FFM in the context of voluntary weight loss is topical and of great interest currently.”
Self-citationClement, D. S. V. M., van Leerdam, M. E., de Jong, S., Weickert, M. O., Ramage, J. K., Tesselaar, M. E. T., & Srirajaskanthan, R. (2023) · Cancers · doi:10.3390/cancers15030782 · Cited by 16 · cited 1×
“The issue of loss of FFM in the context of voluntary weight loss is topical and of great interest currently.”
Self-citationKakehi, S., Tamura, Y., Takeno, K., Ikeda, S., Ogura, Y., Saga, N., Miyatsuka, T., Naıto, H., Kawamori, R., & Watada, H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123951 · Cited by 14 · cited 1×
“This forms the theme for the rest of this review.”
Mutation of spexin2 promotes feeding, somatic growth, adiposity, and insulin resistance in zebrafish
Zhao, T., Ye, Z., Liu, Y., Lin, H., Li, S., & Zhang, Y. (2022) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00307.2021 · Cited by 13 · cited 1×
“In addition to leptin-and adiponectin-related effects on the SM, a further mechanism that contributes towards the development of SO, at least in men, is the increased aromatase expression that occurs within adipocytes in the context of excessive adiposity.”
Al-Rawhani, A. H., Adznam, S. N., Abu Zaid, Z., Md. Yusop, N. B., M. Sallehuddin, H., & Alshawsh, M. A. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.08.033 · Cited by 13 · cited 1×
“In a recently reported rodent-based model, rimonabant—an older centrally acting CB1R inverse agonist—partially restored SM function and induced favourable metabolic changes in the AT and liver [121].”
Fajardo, L., Sanchez, P., Salles, J., Rigaudière, J., Patrac, V., Caspar‐Bauguil, S., Bergoglgio, C., Moro, C., Walrand, S., & Bacquer, O. L. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00258.2022 · Cited by 12 · cited 1×
“For the AMR to have clinical utility, this will require the development of non-invasive and accurate measures of SM and AT mass, ideally performed at the point of care.”
Trivedi, A., Mather, O., Vega, S., Hutton, S., Hellawell, J., & Lee, E. (2022) · Drugs in R&D · doi:10.1007/s40268-022-00386-3 · Cited by 10 · cited 1×
“Such a scenario should prompt a redoubling of management strategies to reduce the AMR, thereby improving cardiometabolic risk, and these types of cases should be prioritised.”
Xiong, Q., Zhang, Y., Li, J., An, Y., & Yu, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305592 · Cited by 10 · cited 1×
“…with the AT) being a key component of obesity pathogenesis and development is under-appreciated, and this misconception places too much emphasis on body weight reduction as a treatment target, rather than the optimisation of body composition and specifically the maintenance of SM mass and function.”
Subcutaneous adipose tissue and skeletal muscle mitochondria following weight loss
van der Kolk, B. W., Pirinen, E., Nicoll, R., Pietiläinen, K. H., & Heinonen, S. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.08.002 · Cited by 10 · cited 1×
“The ‘Mammalian Target of Rapamycin Complex 1’ (mTORC1) is an important nutritionally regulated signalling component that influences mRNA translation and impacts on the insulin-signalling cascade and ultimately on protein synthesis within the SM [85].”
Barber, T. M. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1427580 · Cited by 6 · cited 2×
“The concept of ‘body weight divided by height squared’ as an indicator of body size was originally proposed by Quetelet and was widely adopted as the ‘Body Mass Index’ in the 1980s [11,12].”
Self-citationTsutsui, Y., Itoh, S., Toshima, T., Yoshio, S., Yoshiya, S., Izumi, T., Iseda, N., Toshida, K., Nakayama, Y., Ishikawa, T., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14027 · Cited by 6 · cited 1×
“Spexin is released from the AT and appears to facilitate glucose uptake and lipid metabolism in the SM of animals with T2D or obesity (with reduced serum levels of spexin in these conditions) [56,59].”
(2011) · Europe PMC (PubMed Central)
Cited by
Sepulveda, R. A. Y., Vasquez-Bonilla, A. A., Olivares, R., Olivares, P., Zavala-Crichton, J. P., Hinojosa-Torres, C., Muñoz-Strale, C., Giakoni-Ramírez, F., de Souza-Lima, J., Páez‐Herrera, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-15264-6 · Cited by 18
“These results are unexpected considering that skeletal muscle plays a key role in health and metabolic efficiency 58 .”
Skeletal Muscle Mass Loss and Glucagon-Like Peptide-1 Receptor Agonists: Are Older Patients at Risk?
Kakkar, A. P., Ravussin, É., & LeJemtel, T. H. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03950 · Cited by 7
Longevity, Centenarians, and Lifestyle: Any ‘’Tips’’ to Live Longer?
Vetrani, C., Frias-Toral, E., Annunziata, G., Amatrudo, F., Mayol, D., Suárez, R., Verde, L., Negri, M., Piscitelli, P., Colao, A., et al. (2026) · Current Nutrition Reports · doi:10.1007/s13668-025-00724-2 · Cited by 4
“…increased risk of metabolic disorders and cardiovascular disease [33, 34] Thus, the solution to the BMI paradox is evident: translational geroscience should aim to maximize lean muscle mass and minimize visceral fat, regardless of BMI, in order to optimize the quality of mass over quantity [ 35].”
Stawiarska, A., Francik, R., Mikulec, A. T., Zborowski, M., Cisoń-Apanasewicz, U., Gajdosz, R., Zaczyk, I., Potok, H., Radom, A., Ogonowska, D., et al. (2025) · Metabolites · doi:10.3390/metabo15090591 · Cited by 1
“A decline in muscle mass impairs glucose metabolism, thereby increasing the risk of developing diabetes and metabolic syndrome [13].”
Optimizing Women’s Health Over the Lifespan: Why Body Composition, Bone Health and Fitness Matter
Bovard, R., Nadeau, A. M., Starchook-Moore, M. N., Dabrowski, D. S., Grob, C. H., & Anderson, P. J. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251390867 · Cited by 2
Metadata
- Authors
- Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O.
- Affiliations
- University Hospital Coventry (GB)
- Helmholtz Munich (DE)
- Corresponding author
- Weickert, Martin O.
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2025-02-01
- Volume
- 15
- Issue
- 2
- Pages
- 85
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC11857510
- OpenAlex
- W4407141913
- Cited by
- 19
- References
- 130
- Citations by year
- 2026: 13 · 2025: 6
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Warwick Research Archive Portal (University of Warwick) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Keywords
- obesity, skeletal muscle mass, myokines, adipokines, sarcopenic obesity, insulin resistance, dietary protein, resistance training, negative energy balance, obesity treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.